Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Inclusion criteria for all parts of the study * Confirmation of locally advanced/metastatic cancer. Refractory or resistant to standard therapy, or have no effective standard * Aged at least 18 yrs * Reasonable health (performance status 0 or 1), stable over the previous 2 weeks * Females who can have children must use contraception; have a negative pregnancy test, \& not be breast feeding * Sexually active male patients must use contraception for duration of study and for 3 months afterwards Inclusion criteria for Part B only * Tumour(s) that can be measured by CT or MRI, at least 1cm in size Inclusion Part B * Confirmation of metastatic/locally advanced cancer of specific tumour type which failed to respond to standard treatments Exclusion criteria for all parts of the study * Prior treatment with an ATM inhibitor * Past medical history of an inflammatory type(interstitial) lung disease or current inflammatory lung disease * Radiotherapy within the last 4 weeks, except palliative radiotherapy for bone pain relief * Prior treatment with drugs that may cause lung damage * Poor of lung function * History/presence of muscle weakness or abnormal blood tests relating to muscle function * Cancer affecting the spinal cord and/or brain unless asymptomatic and stable * Any evidence of severe or uncontrolled diseases, active bleeding,kidney transplant, or active infection including liver infections (hepatitis B, hepatitis C) and human immunodeficiency virus (HIV). * Evidence of severe lung infections * Receiving, or having received during the four weeks prior to starting study treatment other chemotherapy treatment for your cancer * Treatment with certain doses of steroids during the two weeks prior to starting study treatment * A known sensitivity to AZD0156 or any of its components * Treatment with any unapproved medicine within 28 days prior to starting study treatment * Receiving, or having received medications, herbal supplements and/or foods that significantly affect how your liver works * Low numbers of certain blood cells * If your liver and kidney aren't working normally * If your heart isn't working normally or you have a strong family history of certain heart diseases * Other cancers within the past 3 years, except for certain types of cervical and skin cancers * Sickness and vomiting, digestive diseases or previous significant bowel removal * Patients with uncontrolled fitting * Infections requiring treatment * Other severe and/or uncontrolled medical conditions in addition to your cancer * A blockage in your digestive system or severe bleeding from the stomach within 4 weeks before your take medication on the stuy * Patients with acute leukaemia or certain bone marrow diseases * Patients with a known sensitivity to olaparib or its components (Module 1), or components of FOLFIRI (Module 2) * Any previous treatment with drugs that work like olaparib. (Module 1 Only)